Targeting α-synuclein as a therapeutic strategy for Parkinsons disease

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 10, 2015, Pages 1351-1360

  Lawand, Nada B ^a   Saadé, Nayef E ^a   El Agnaf, Omar M ^b   Safieh Garabedian, Bared ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

^c QATAR UNIVERSITY   (Qatar)

Author keywords

immunotherapy; inflammation; Lewy bodies; neurodegenerative disorder; Parkinson's disease; synucleinopathies; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; IMMUNOMODULATING AGENT;

DEGENERATIVE DISEASE; DISEASE COURSE; GENE MUTATION; HUMAN; IMMUNOTHERAPY; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SYNUCLEINOPATHY; ANIMAL; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES; QUALITY OF LIFE;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PARKINSON DISEASE; QUALITY OF LIFE; SIGNAL TRANSDUCTION;

EID: 84941798927     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1062877     Document Type: Review

References (97)

1. Pellicano C, Benincasa D, Pisani V, et al. Prodromal non-motor symptoms of Parkinsons disease. Neuropsychiatr Dis Treat 2007; 3: 145-51
2. Milber JM, Noorigian JV, Morley JF, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 2012; 79: 2307-14
3. Liu Q, Emadi S, Shen JX, et al. Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein. PLoS ONE 2013; 8 (2): e55886
4. Daher JPL, Volpicelli-Daley LA, Blackburn JP, et al. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. PNAS 2014; 25: 9289-94
5. Kermer P, Köhn A, Schnieder M, et al. BAG1 is neuroprotective in in vivo and in vitro models of Parkinsons disease. J Mol Neurosci 2015; 55 (3): 587-95
6. Al-Mansoori KM, Hasan MY, Al-Hayani A, et al. The role of α-synuclein in neurodegenerative diseases: From molecular pathways in disease to therapeutic approaches. Curr Alz Res 2013; 10 (6): 559-68
7. Mullin S, Schapira AH. Pathogenic mechanisms of neurodegeneration in Parkinson disease. Neurol Clin 2015; 33: 1-17
8. Spillantini MG, Schmidt ML, Lee VMY, et al. α-synuclein in Lewy bodies. Nature 1997; 388: 839-40
9. Raslan AA, Kee Y. Tackling neurodegenerative diseases: animal models of Alzheimers disease and Parkinsons disease. Genes Genom 2013; 35: 425-40
10. Hall K, Yang S, Sauchanka O, et al. Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) α-synuclein. Exp Neurol 2015; 264: 8-13
11. Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of α-synuclein oligomers reveals previously undetected pathology in Parkinsons disease brain. Brain 2015; 138 (Pt 6): 1642-57
12. Watson JB, Hatami A, David H, et al. Alterations in corticostriatal synaptic plasticity in mice overexpressing human α-synuclein. Neurosci 2009; 159: 501-13
13. Murphy DD, Rueter SM, Trojanowski JQ, et al. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000; 20 (9): 3214-20
14. Lashuel HA, Overk CR, Oueslati A, et al. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2013; 14: 38-48
15. Perez RG, Waymire JC, Lin E, et al. A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002; 22: 3090-9
16. Alerte TN, Akinfolarin AA, Friedrich EE, et al. α-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci Lett 2008; 43: 24-9
17. Zhou RM, Huang YX, Li XL, et al. Molecular interaction of α-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells. Mol Biol Rep 2010; 37: 3183-92
18. Bartels T, Choi JG, Selkoe DJ. α-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011; 477: 107-10
19. Spinelli KJ, Taylor JK, Osterberg VR, et al. Presynaptic α-synuclein aggregation in a mouse model of Parkinsons disease. J Neurosci 2014; 34: 2037-50
20. Swirski M, Miners JS, de Silva R, et al. Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinsons disease. Alz Res Ther 2014; 6 (5-8): 77
21. Cavallarin N, Vicario M, Negro A. The role of phosphorylation in synucleinopathies: focus on Parkinsons disease. CNS Neurol Disord Drug Targets 2010; 9 (4): 471-81
22. Kosten J, Binolfi A, Stuiver M, et al. Efficient modification of α-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event. ACS Chem Neurosci 2014; 5: 1203-8
23. Khodr CE, Becerra A, Han Y, et al. Targeting α-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res 2014; 1550: 47-60
24. Khodr CE, Sapru MK, Pedapati J, et al. An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinsons disease, but displays toxicity in dopamine neurons. Brain Res 2011; 1395: 94-107
25. Schade S, Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimers Res Ther 2014; 6 (5-8): 72
26. Hall S, Surova Y, Öhrfelt A, et al. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015; 84: 57-63
27. Parnetti L, Castrioto A, Chiasserini D, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nature Rev Neurol 2013; 9: 131-40
28. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinsons disease. FASEB J 2006; 20: 419-25
29. Wang N, Gibbons CH, Lafo J, et al. α-synuclein in cutaneous autonomic nerves. Neurology 2013; 81: 1604-10
30. Gibbons C, Wang N, Freeman R. α-synuclein within cutaneous autonomic nerves in Parkinson disease: A biomarker of disease severity and autonomic dysfunction. Neurology 2014; 82 (10): S37007
31. Visanji NP, Marras C, Kern DS, et al. Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015; 84 (6): 609-16
32. Ardah MT, Paleologou KE, Lv G, et al. Ginsenoside Rb1 inhibits fibrillation and toxicity of α-synuclein and disaggregates preformed fibrils. Neurobiol Dis 2015; 74: 89-101
33. Tóth G, Gardai SJ, Zago W, et al. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinsons disease. PLoS ONE 2014; 9: e87133
34. Lopez de Maturana R, Aguila JC, Sousa A, et al. Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinsons disease. Neurobiol Aging 2014; 35: 1116-24
35. Dzamko N, Zhou J, Huang Y, et al. Parkinsons disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci 2014; 7: 57
36. Braithwaite SP, Stock JB, Mouradian MM. α-Synuclein phosphorylation as a therapeutic target in Parkinsons disease. Rev Neurosci 2012; 23: 191-8
37. Pérez-Revuelta BI, Hettich MM, Ciociaro A, et al. Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis 2014; 5: e1209
38. Angot E, Brundin P. Dissecting the potential molecular mechanisms underlying α-synuclein cell-to-cell transfer in Parkinsons disease. Parkinsonism Relat Disord 2009; 15 (3): S143-7
39. Lee SJ, Desplats P, Sigurdson C, et al. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 2010; 6: 702-6
40. Dunning CJR, George S Brundin P. Whats to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease? Prion 2013; 7: 92-7
41. Kovacs GG, Breydo L, Green R, et al. Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiology of Dis 2014; 69: 76-92
42. Bétemps D, Verchère J, Brot S, et al. Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA. Acta Neuropathol Commun 2014; 2: 29-43
43. Chu Y and Kordower JH. The prion hypothesis of Parkinsons Disease. Curr Neurol Neurosci Rep 2015; 15: 28-38
44. Sacino AN, Brooks M, Thomas MA, et al. Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol 2014; 127: 645-65
45. Valera E, Masliah E. Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther 2013; 138: 311-22
46. Romero-Ramos M, von Euler Chelpin M, Sanchez-Guajardo V. Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Hum Vaccin Immunother 2014; 10: 852-67
47. Glenner GG, Wong CW. Alzheimers disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-90
48. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc Natl Acad Sci USA 2009; 106: 13010-15
49. Brannstrom K, Lindhagen-Persson M, Gharibyan AL, et al. A generic method for design of oligomer-specific antibodies. PLoS ONE 2014; 9: e90857
50. Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an α-synuclein transgenic model of Lewy body disease. PLoS One 2011; 6: e19338
51. Näsström T, Goncąlves S, Sahlin C, et al. Antibodies against α-synuclein reduce oligomerization in Living. PLoS ONE 2011; 6 (10): e27230
52. Vekrellis K, Stefanis L. Targeting intracellular and extracellular α-synuclein as a therapeutic strategy in Parkinsons disease and other synucleinopathies. Expert Opin Ther Targets 2012; 16 (4): 421-32
53. Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012; 32: 13454-69
54. Tran HT, Chung CH-Y, Iba M, et al. α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Reports 2014; 7: 2054-65
55. Lindström V, Fagerqvist T, Nordström E, et al. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol Dis 2014; 69: 134-43
56. Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated α-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinsons disease-like models. J Neurosci 2014; 34: 9441-54
57. Mandler M, Valera E, Rockenstein E, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinsons disease clinical trials. Acta Neuropathol 2014; 127: 861-79
58. De Genst E, Messer A, Dobson CM. Antibodies and protein misfolding: From structural research tools to therapeutic strategies. Biochem Biophys Acta 2014; 1844: 1907-19
59. Bhatt MA, Messer A, Kordower JH. Can intrabodies serve as neuroprotective therapies for Parkinsons disease? Beginning thoughts. J Parkinsons Dis 2013; 3: 581-91
60. Messer A, Joshi SN. Intrabodies as neuroprotective therapeutics. Neurotherapeutics 2013; 10: 447-58
61. Ladiwala AR, Bhattacharya M, Perchiacca JM, et al. Rational design of potent domain antibody inhibitors of amyloid fibril assembly. Proc Natl Acad Sci USA 2012; 109 (49): 19965-70
62. Safieh-Garabedian B, Haddad JJ, Saadé NE. Cytokines in the central nervous system: Targets for therapeutic intervention. Current Drug Targets CNS Neurol Disord 2004; 3 (4): 271-80
63. Chao Y, Wong SC, Tan EK. Evidence of inflammatory system involvement in Parkinsons disease. Biomed Res Int 2014; 2014: 308654
64. Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. The relation between α-synuclein and microglia in Parkinsons disease: recent developments. Neuroscience 2015
65. Doorn KJ, Lucassen PJ, Boddeke HW, et al. Emerging roles of microglial activation and non-motor symptoms in Parkinsons disease. Prog Neurobiol 2012; 98: 222-38
66. Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinsons disease. J Neuroimmune Pharmacol 2013; 8: 189-201
67. Yan J, Fu Q, Cheng L, et al. Inflammatory response in Parkinsons disease (Review). Mol Med Reports 2014; 10 (5): 2223-33
68. Kim C, Ho DH, Suk JE, et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 2013; 4: 1562
69. Barkholt P, Sanchez-Guajardo V, Kirik D, et al. Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates. Neuroscience 2012; 208: 85-96
70. Macchi B, Paola DR, Marino-Merlo F, et al. Inflammatory and cell death pathways in brain and peripheral blood in Parkinsons disease. CNS Neurol Disord Drug Targets 2015; 14 (3): 313-24
71. Fellner L, Irschick R, Schanda K, et al. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia 2013; 61: 349-60
72. Codolo G, Plotegher N, Pozzobon T, et al. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS ONE 2013; 8: e55375
73. Alvarez-Erviti L, Couch Y, Richardson J, et al. α-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res 2011; 69: 337-42
74. Sanchez-Guajardo V, Barnum CJ, Tansey MG, et al. Neuroimmunological processes in Parkinsons disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 2013; 5 (2): 113-39
75. Decressac M, Mattsson B, Björklund A. Comparison of the behavioral and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinsons disease. Exp Neurol 2012; 235: 306-15
76. Allen Reish HE, Standaert DG. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 2015; 5 (1): 1-19
77. Kannarkat T, Boss GT, Tansey MG. The role of innate and adaptive immunity in Parkinsons Disease. J Parkinsons Dis 2013; 3 (4): 493-514
78. Sica RE. Could astrocytes be the primary target of an offending agent causing the primary degenerative diseases of the human central nervous system? A hypothesis. Med Hypothesis 2015; 84 (5): 481-9
79. Lee HJ, Suk JE, Patrick C, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010; 285: 9262-72
80. Sathe K, Maetzler W, Lang JD, et al. S100B is increased in Parkinsons disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain 2012; 135: 3336-47
81. Mcgeer PL, Mcgeer EG. Glial reactions in Parkinsons disease. Mov.Disord 2008; 23: 474-83
82. Braak H, Sastre M, Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinsons disease. Acta Neuropathol 2007; 114: 231-41
83. Safieh-Garabedian B, Ochoa-Chaar CI, Poole S, et al. Thymulin reverses inflammatory hyperalgesia and modulates the increased concentration of proinflammatory cytokines induced by I.C.V. endotoxin injection. Neuroscience 2003; 121: 865-73
84. Safieh-Garabedian B, Jabbur SJ, Dardenne M, et al. Thymulin related peptide attenuates inflammation in the brain induced by intracerebroventricular endotoxin injection. Neuropharmacology 2011; 60: 496-504
85. Harms AS, Barnum CJ, Ruhn KA, et al. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinsons disease. Mol Ther 2011; 19: 46-52
86. Barnum CJ, Chen X, Chung J, et al. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. J Parkinsons Dis 2014; 4: 349-60
87. Gerard M, Deleersnijder A, Daniëls V, et al. Inhibition of FK506 binding proteins reduces α-synuclein aggregation and Parkinsons disease-like pathology. J Neurosci 2010; 30: 2454-63
88. Van der Perren A, Macchi F, Toelen J, et al. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinsons disease. Neurobiol Aging 2015; 36 (3): 1559-68
89. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinsons disease. J Clin Invest 2013; 123: 2730-6
90. Foltynie T, Aviles-Olmos I. Exenatide as a potential treatment for patients with Parkinsons disease: first steps into the clinic. Alzheimers Dement 2014; 10 (1): S38-46
91. Kettenmann H, Hanisch UK, Noda M, et al. Physiology of microglia. Physio Rev 2011; 91: 461-553
92. Kwilasz AJ, Grace PM, Serbedzija P, et al. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology 2014
93. Joniec-Maciejak I, Ciesielska A, Wawern A, et al. The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinsons disease. Pharmacol Rep 2014; 66: 660-9
94. Boza-Serrano A, Reyes JF, Rey NL, et al. The role of Galectin-3 in α-synuclein-induced microglial activation. Acta Neuropathol Commun 2014; 2: 156
95. Recasens A, Dehay B, Bové J, et al. Lewy body extracts from Parkinson disease brains trigger α-Synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014; 75: 351-62
96. de Calignon A, Fox LM, Pitstick R, et al. Caspase activation precedes and leads to tangles. Nature 2010; 464 (7292): 1201-4
97. McKinnon C, Tabrizi SJ. The ubiquitin-proteasome system in neurodegeneration. Antioxid Redox Signal 2014; 21 (7): 2302-21